Dr. Reddy’s Laboratories (RDY) is a major player in the generic drugs markets. The company reports its financial performance under three operating segments — Global Generics, Pharmaceutical Services & Active Ingredients and Others.Let’s delve deeper to discuss four reasons why adding Dr. Reddy’s stock to your portfolio may prove beneficial in fiscal 2025.RDY Boasts a Strong Pipeline of Generic DrugsDr. Reddy’s enjoys a strong position in the generics market. As of Sept. 30, 2024, cumulatively, 80 generic fi ...

Dr. Reddy’s Laboratories (RDY) announced that it has launched a biosimilar of Coherus BioSciences’ (CHRS) Loqtorzi (toripalimab) in India under the brand name Zytorvi for the treatment of adults with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC), a rare form of head and neck cancer.Loqtorzi, a novel anti-PD-1 monoclonal antibody, is a new biological entity that has been developed by Coherus in collaboration with China-based Junshi Biosciences. In October 2023, CHRS announced the FDA’s approval o ...

Dr. Reddy's Laboratories Limited (NYSE:RDY) Q2 2025 Earnings Conference Call November 5, 2024 9:00 AM ET Company Participants Richa Periwal - Head of Investor Relations MV Narasimham - Chief Financial Officer Erez Israeli - Chief Executive Officer Conference Call Participants Kunal Dhamesha - Macquarie Neha Manpuria - Bank of America Amey Chalke - JM Financial Mikaela Franceschina - Barclays Harith Ahmad - Avendus Spark Damayanti Kerai - HSBC Bino Pathiparampil - Elara Capital Surya Patra - PhillipCapital T ...

Q2FY25 FINANCIAL RESULTS 1 November 5, 2024 Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements that are other than statements of historical fact, including, but not limited to, those that are identified by the use of words such as "anticipates", ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor. Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style Scores? The ...

Dr. Reddy's Laboratories (RDY) signed a non-binding Memorandum of Understanding (MoU) with Kainomyx, Inc. to develop and commercialize affordable anti-malarial drug in the United States, EU and low and middle-income countries. Kainomyx is a U.S.-based company that utilizes its proprietary platform to develop candidates with a novel mechanism of action. Per Dr. Reddy's, the MoU is subject to the signing of a definitive agreement. There is a significant unmet medical need in the treatment of malaria and other ...

1 IF D H HT T 100 - 100 1 i T 1 Pgiam/iStock via Getty Images Investment update Following my last publication on Dr. Reddy's Laboratories Limited (NYSE:RDY), the stock has advanced another 29% to the upside. Shares are now +20% this year to date, and there are now multiple additional tailwinds adding to the business momentum. These include 1) the company's Q1 FY'25 numbers and 2) the legislative tailwinds made possible by the Affordable Prescriptions for Patients Act passed in the US Senate in July '24. I c ...

Dr. Reddy's Laboratories Limited (RDY) reported first-quarter fiscal 2025 earnings of $1 per American Depositary Share (ADS), which missed the Zacks Consensus Estimate of $1.10 per ADS. The company reported earnings of $1.01 per ADS in the year-ago quarter. Quarter in Detail Shares of Dr. Reddy's have gained 16.7% year to date compared with the industry's 14.5% growth. Dr. Reddy's reports revenues under three segments: Global Generics, Pharmaceutical Services & Active Ingredients (PSAI) and Others. As of Ju ...

Dr. Reddy's Laboratories Limited (NYSE:RDY) Q1 2025 Earnings Conference Call July 27, 2024 7:00 AM ET Conference Call Participants I now hand the conference over to Mr. Richa Periwal. Thank you and over to you. Richa Periwal - Head of Investor Relations Parag Agarwal - Chief Financial Officer Erez Israeli - Chief Executive Officer MV Narasimham - Deputy Chief Financial Officer Operator Richa Periwal Thank you. A very good morning and good evening to all of you and thank you for joining us today for the Dr. ...

The strategic move is set to further strengthen Dr. Reddy's OTC business. Please note that Haleon's Nicotinell is the world's second-largest brand in the NRT category, excluding the United States. It holds either the first or second position in 14 out of the top 17 global markets, with its lozenge/mini lozenge format being the top choice globally. Additionally, Nicotinell is among the top 15 OTC brands in Europe (excluding Russia and Italy) and ranks 32nd among all OTC brands globally (excluding the United ...